The Clinical Diagnostics Service of the Molecular Otolaryngology and Renal Research Laboratories is a CLIA-approved, Joint Commission-accredited diagnostic laboratory.
Plasma Complement Factor I Level
Atypical Hemolytic Uremic Syndrome
Complement Factor I (FI; MW: 88 kDa) is an important regulator of complement activity triggered through the classical and alternative pathways. FI limits complement activation by cleaving surface-bound and fluid-phase C3b and C4b, preventing the assembly of the C3 and C5 convertases. Patients with FI mutations may have reduced plasma FI levels and/or function, and are at-risk to develop atypical hemolytic uremic syndrome or C3 glomerulopathy.
Indications for screening
Testing is appropriate for patients with aHUS.
MORL screening methodology
Enzyme Linked Immuno-Sorbent Assay (ELISA)
Turnaround time is ~2 weeks.
1 ml frozen EDTA plasma (see testing requisition for specimen handling).
Cost & CPT Codes
See the MORL Testing Menu